Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene FGFR2
Variant K310R
Impact List missense
Protein Effect gain of function - predicted
Gene Variant Descriptions FGFR2 K310R lies within Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). K310R results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function.
Associated Drug Resistance
Category Variants Paths

FGFR2 mutant FGFR2 act mut FGFR2 K310R

FGFR2 mutant FGFR2 exon7 FGFR2 K310R

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_000141.5
gDNA chr10:g.121519989T>C
cDNA c.929A>G
Protein p.K310R
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_022970.3 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
XM_017015925.2 chr10:g.121515187T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_000141 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_022970.4 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
XM_017015924.3 chr10:g.121515187T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_001144917 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
XM_024447891.1 chr10:g.121515190T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_001144917.2 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_001144913 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
XM_024447891.2 chr10:g.121515190T>C c.929A>G p.K310R RefSeq GRCh38/hg38
XM_017015925.3 chr10:g.121515187T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_001320658.1 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
XM_017015925 chr10:g.121515187T>C c.929A>G p.K310R RefSeq GRCh38/hg38
XM_006717712 chr10:g.121515190T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_022970 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_001144913.1 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
XM_017015924.2 chr10:g.121515187T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_000141.5 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_001144917.1 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_000141.4 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_001320658.2 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_001144913.1 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
NM_001320658 chr10:g.121519989T>C c.929A>G p.K310R RefSeq GRCh38/hg38
XM_017015924 chr10:g.121515187T>C c.929A>G p.K310R RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 K310R FGFR2 N549K endometrial carcinoma sensitive FIIN-1 Preclinical Actionable In a preclinical study, FIIN-1 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K and FGFR2 K310R mutations in culture (PMID: 20338520). 20338520
FGFR2 K310R FGFR2 N549K endometrial cancer sensitive Debio 1347 Preclinical Actionable In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 K310R and FGFR2 N549K mutations in culture (PMID: 25169980). 25169980
FGFR2 K310R FGFR2 N549K endometrial carcinoma no benefit RO4987655 Preclinical - Cell culture Actionable In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO4987655 in culture (PMID: 26438159). 26438159
FGFR2 K310R FGFR2 N549K endometrial carcinoma no benefit RO5126766 Preclinical - Cell culture Actionable In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO5126766 in culture (PMID: 26438159). 26438159
FGFR2 K310R FGFR2 N549K endometrial carcinoma no benefit Selumetinib Preclinical - Cell culture Actionable In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159). 26438159
FGFR2 K310R FGFR2 N549K endometrial cancer predicted - sensitive Futibatinib Preclinical - Cell culture Actionable In a preclinical study, Lytgobi (futibatinib) treatment led to inhibition of cell proliferation in an endometrial cancer cell line harboring FGFR2 K310R and FGFR2 N549K in culture (PMID: 32973082). 32973082
FGFR2 K310R FGFR2 N549K endometrial adenocarcinoma sensitive RLY-4008 Preclinical - Cell line xenograft Actionable In a preclinical study, RLY-4008 inhibited proliferation of an endometrial adenocarcinoma cell line harboring FGFR2 N549K and FGFR K310R in culture, and led to tumor regression in a cell line xenograft model (PMID: 37270847). 37270847
FGFR2 K310R FGFR2 N549K endometrial adenocarcinoma sensitive Futibatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Lytgobi (futibatinib) treatment led to tumor regression in a cell line xenograft model of endometrial adenocarcinoma harboring FGFR2 N549K and FGFR2 K310R (PMID: 37270847). 37270847
FGFR2 K310R FGFR2 N550K endometrial cancer sensitive AZD4547 Preclinical - Cell line xenograft Actionable In a preclinical study, AZD4547 inhibited proliferation of endometrial cancer cells harboring an FGFR2 K310R/N550K double mutation in culture and delayed tumor growth in xenograft models (PMID: 26294741). 26294741
FGFR2 K310R FGFR2 N550K endometrial cancer sensitive AZD4547 Preclinical - Cell culture Actionable In a preclinical study, AZD4547 treatment induced cell death and reduced survival of an endometrial cancer cell line harboring FGFR2 N550K and K310R in culture (PMID: 30537101). 30537101
FGFR2 K310R FGFR2 N550K endometrial cancer sensitive Infigratinib + Navitoclax Preclinical - Cell line xenograft Actionable In a preclinical study, Truseltiq (infigratinib) and Navitoclax (ABT-263) combination treatment enhanced apoptosis, and inhibited tumor growth and induced regression in a cell line xenograft model of endometrial cancer harboring FGFR2 K310R and N550K compared to either agent alone (PMID: 30537101). 30537101
FGFR2 K310R FGFR2 N550K endometrial cancer sensitive Infigratinib Preclinical - Cell line xenograft Actionable In a preclinical study, Truseltiq (infigratinib) treatment induced cell death and reduced survival of an endometrial cancer cell line harboring FGFR2 N550K and K310R in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 30537101). 30537101
FGFR2 K310R FGFR2 N550K endometrial cancer sensitive PD173074 Preclinical - Cell culture Actionable In a preclinical study, PD173074 treatment induced cell death and reduced survival of an endometrial cancer cell line harboring FGFR2 N550K and K310R in culture (PMID: 30537101). 30537101
FGFR2 K310R FGFR2 N550K endometrial cancer sensitive ABT-737 + AZD4547 Preclinical - Cell culture Actionable In a preclinical study, an endometrial cancer cell line harboring FGFR2 N550K and K310R demonstrated increased cell death following treatment with AZD4547 and ABT-737 combination compared to either agent alone in culture (PMID: 30537101). 30537101
FGFR2 K310R FGFR2 N550K endometrial cancer sensitive ABT-737 + Infigratinib Preclinical - Cell culture Actionable In a preclinical study, an endometrial cancer cell line harboring FGFR2 N550K and K310R demonstrated increased cell death following treatment with Truseltiq (infigratinib) and ABT-737 combination compared to either agent alone in culture (PMID: 30537101). 30537101
FGFR2 K310R FGFR2 N550K endometrial cancer sensitive ABT-737 + PD173074 Preclinical - Cell culture Actionable In a preclinical study, an endometrial cancer cell line harboring FGFR2 N550K and K310R demonstrated increased cell death following treatment with PD173074 and ABT-737 combination compared to either agent alone in culture (PMID: 30537101). 30537101